RED: National Orbis Drug Access Arrangements – sotorasib as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) exhibiting a KRAS G12C mutation and who have been previously treated with at least 1 prior systemic therapy for advanced NSCLC
RED: NICE TA781 - Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (Decision date - April 2022)